MISSION:​              Address the Growing Unmet Need

     Associated with Substance Use Disorder

     By Discovering, Developing and Commercializing
    Safe and Effective Pharmacotherapies
    to Treat and Prevent Addiction

Peter Strumph, Chief Executive Officer and Founder

  • Former SVP Operations, Portola Pharmaceuticals; CEO, Codexis; CEO, Nile Therapeutics; SVP Operations, CVT; Operations Planning, Biogen; Lieutenant, US Navy


Amygdala Neurosciences Acquires GS-6637 from Gilead

Ivan Diamond, MD, PhD, Chief Scientific Officer and Founder

  • Former Senior Advisor, Gilead Sciences; VP Neurology Research, CVT;  Vice Chair, UCSF Department of Neurology; Founding Director, UCSF Ernest Gallo Clinic and Research Center

In addition to Lou Lange, Ivan Diamond, and Peter Strumph, the BOD includes:

William Lee, PhD, Executive Vice President Research, Gilead Sciences
Howard Jaffe, MD, President and COB of the Gilead Foundation. Former CMO Gilead Sciences


The Amygdala founders have deep and varied expertise in drug development and the addiction space. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.

The Board of Directors

Mack Mitchell, MD, Chief Medical Officer

  • EVP of Health System at the University of Texas Southwestern Medical Center; former Chief of Gastroenterology and the Medical Director of Ambulatory Services at Johns Hopkins Bayview Medical Center

The Team

Adrienne MacMillan, Chief Financial Officer and Founder

  • Former CFO, Rapidscan Pharma Solutions; VP Finance, CVT

Brent Blackburn, PhD, Chief Development Officer and Founder

  • Former CEO, Rapidscan Pharma; SVP R&D, CVT

Lou Lange, MD, PhD, Executive Chairman and Founder

  • General Partner Asset Management; Senior Advisor to CEO, Gilead Sciences
  • Former Founder Chairman & CEO, CV Therapeutics; Chief of Cardiology and Professor of Medicine at Jewish Hospital Washington University

ANS-6637 is in Phase 2 Clinical Development to Treat Substance Use Disorders

ANS-6637 is a new chemical entity selective and reversible ALDH2 inhibitor. Based on its mechanism of action in the brain to prevent pathophysiologic dopamine surge without changes to basal dopamine (Nature Medicine 16:1024, 2010), ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In preclinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anti-anxiety properties in models of stress.

Amygdala acquired the asset ANS-6637 as a spin out from Gilead Sciences. ANS-6637 has completed extensive Phase 1 studies in 150 human subjects. ANS-6637 is currently in Phase 2 clinical development for alcohol use disorder with plans to start additional Phase 2 studies in opioid use disorder and smoking cessation.